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Abstract
Background: Evidence has accumulated that multiple genetic and environmental factors play important roles in
determining susceptibility to type 2 diabetes (T2D). Although variants from candidate genes have become prime targets for
genetic analysis, few studies have considered their interplay. Our goal was to evaluate interactions among SNPs within
genes frequently identified as associated with T2D.
Methods/Principal Findings: Logistic regression was used to study interactions among 4 SNPs, one each from
HNF4A[rs1884613], TCF7L2[rs12255372], WFS1[rs10010131], and KCNJ11[rs5219] in a case-control Ashkenazi sample of 974
diabetic subjects and 896 controls. Nonparametric multifactor dimensionality reduction (MDR) and generalized MDR
(GMDR) were used to confirm findings from the logistic regression analysis. HNF4A and WFS1 SNPs were associated with
T2D in logistic regression analyses [P,0.0001, P,0.0002, respectively]. Interaction between these SNPs were also strong
using parametric or nonparametric methods: the unadjusted odds of being affected with T2D was 3 times greater in
subjects with the HNF4A and WFS1 risk alleles than those without either (95% CI=[1.7–5.3]; P#0.0001). Although the
univariate association between the TCF7L2 SNP and T2D was relatively modest [P=0.02], when paired with the HNF4A SNP,
the OR for subjects with risk alleles in both SNPs was 2.4 [95% CI=1.7–3.4; P#0.0001]. The KCNJ11 variant reached
significance only when paired with either the HNF4A or WFSI SNPs: unadjusted ORs were 2.0 [95% CI=1.4–2.8; P#0.0001]
and 2.3 [95% CI=1.2-4.4; P#0.0001], respectively. MDR and GMDR results were consistent with the parametric findings.
Conclusions: These results provide evidence of strong independent associations between T2D and SNPs in HNF4A and
WFS1 and their interaction in our Ashkenazi sample. We also observed an interaction in the nonparametric analysis between
the HNF4A and KCNJ11 SNPs (P#0.001), demonstrating that an independently non-significant variant may interact with
another variant resulting in an increased disease risk.
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Introduction
Type 2 diabetes (T2D) has become one of the leading and
fastest growing health problems in the world affecting approxi-
mately 18 million Americans and over 170 million individuals
worldwide in 2000. By 2030 these estimates are expected to rise to
over 30 million in the United States and 366 million worldwide
[www.who.int/diabetes/facts/world_figures]. Although its exact
etiology is unknown, accumulating evidence recognizes T2D as a
quintessential multifactorial disease, resulting from numerous inter-
actionsbetween multiplegeneticvariants,alongwithenvironmental
factors related to diet, exercise, stress, and medical treatment [1].
Givenitspositionasoneoftheleadinghealth problemsintheworld,
in the last few years T2D has been the target of 15 genome wide
association studies (GWAS) [2] and multiple candidate gene studies
(reviewed in [3] and [4]). These studies have been successful in
identifying individual variants in a variety of genes that may play
a role in the etiology of T2D. However, because of practical
and statistical challenges, none of the GWAS have considered
interactions among the thousands of GWA variants, and only
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[5–13]. These studies generally include only those variants in their
interaction analyses that have shown some nominal probability of
marginal significance (e.g. p,0.05) in previous studies. However,
there are genetic models in which variants show no independent
association with the trait of interest, butwhich, inconcert with other
variants, do provide evidence of interaction effects [14]. This
phenomenon has also been studied and documented in animal
models [15,16].
In the present study we investigated the importance of gene-
gene interplay on type 2 diabetes in a case-control sample of
Ashkenazi subjects. Four genes, TCF7L2, HNF4A, KCNJ11, and
WFS1, all with strong prior evidence for association with T2D and
with credible biological mechanistic effects on T2D, were chosen
for analysis. One Single Nucleotide Polymorphism (SNP) was
selected for genotyping from each of these four candidate genes
based on previous studies in which the SNP was shown to be
directly associated with T2D or in high linkage disequilibrium with
a SNP identified as associated with T2D. SNPs in the TCF7L2
gene were selected as being the only truly universally T2D positive
SNPs that had been identified at the start of this study. Two
intronic SNPs in high LD (r
2=0.77) in the TCF7L2 gene,
rs12255372 and rs7903146, had been identified as being
associated with T2D in at least 49 articles. We chose to genotype
rs12255372 in our Ashkenazi population. HNF4A is a transcrip-
tion factor regulating a network of genes controlling insulin
secretion and glucose regulation. Recently we have found the
HNF4A SNP, rs1884613, to be strongly associated with T2D in an
Ashkenazi case-control sample unrelated to the sample in our
current study [17]. Rs1884613 is located upstream of HNF4A and
has no known function. The potassium channel gene, KCNJ11 on
chromosome 11p15.1, regulates glucose-induced insulin secretion
in pancreatic beta cells [18–20]. With the exception of Ashkenazi
samples, coding SNP rs5219 (E23K) in KCNJ11 has been
consistently associated with T2D populations over many years
[21]. We included this SNP in our analysis to determine if its effect
might be amplified by interactions with other genes in the
Ashkenazi population. Although mutations in the WFS1 gene
have long been known to be causal in autosomal recessive
Wolfram syndrome [22], recently several studies have implicated
WFS1 SNPs also to be associated with T2D [23–26]. Four of the
five PubMed citations for T2D studies using rs10010131 found
evidence for an association with T2D, including a meta analysis of
previous studies from Sweden, Finland, and France, which
reported a highly significant finding for this SNP [23]. In addi-
tion, rs10010131 was one of 2 intronic WFS1 SNPs in strong
disequilibrium (r
2=0.98) found to be significant in a study of T2D
in UK and Ashkenazi populations studying genes involved in
pancreatic b cell function [25] in both populations. Our multilocus
analysis strategy makes use of the traditional parametric approach
of logistic regression and the nonparametric method of multifactor
dimensionality reduction (MDR) [27].
Methods
Ethics Statement
This study was approved by the local ethics committee of each
center where samples were collected: the committee on Research
Involving Human Subjects of The Hebrew University-Hadassah
Medical School, Jerusalem, Israel; Committee on Clinical
Investigations at Albert Einstein College of Medicine; the Human
Research Protection Office at Washington University in St. Louis.
Written informed consent was obtained from all participants
before participation in the study.
Samples
To minimize potential genetic heterogeneity, 1,870 subjects
(974 cases, 896 controls) were recruited for a cross-sectional study
from the Ashkenazi Jewish population. Blood was drawn from all
subjects, and age of diagnosis was determined for cases by
questionnaire and review of medical history. Subjects had been
determined to have T2D if their fasting glucose was greater than
140 mg/dl on more than 1 occasion or random glucose was
greater than 200 mg/dl on at least two occasions [28]. Ashkenazi
Jews are a relatively homogeneous population thought to have
developed from a founder population approximately 500 years ago
[29]. Subjects who self identified as Ashkenazi were accepted into
the study only if all four grandparents also self identified as
Ashkenazi and were born in Northern or Eastern Europe. Most of
the subjects in this study reside in Israel (N=1,600); the remainder
are United States citizens residing in New York City, ascertained
from the Einstein Longevity Study [30,31]. The NYC portion of
our sample contained, with one exception, only controls. Sex,
body mass index (BMI) and current smoking status were available
for possible inclusion in the analyses.
DNA samples for the Israeli Ashkenazi subjects were obtained
from Dr. Benjamin Glaser and genotyping data from the NYC
sample were obtained from Dr. Gil Atzmon. Genotypes for Israeli
Ashkenazim SNPs were assessed by PCR amplification of genomic
DNA and Pyrosequencing technology (Biotage AB, Uppsala,
Sweden) as previously described [32]. Genotypes for the NYC
sample were assessed by Pyrosequencing technology (Biotage AB,
Uppsala, Sweden) as discussed in [33].
Data Analyses
Exact Hardy Weinberg Equilibrium (HWE) tests were per-
formed for each SNP independently among cases and controls.
Logistic regression models (SAS V9.1.3) were used to assess the
effects of each of the 4 SNPs on T2D with and without adjusting
for sex and body mass index (BMI). Smoking status was available
for over 98% of controls, but only 25% of cases and therefore was
not included in the data analyses. An additive model was used to
code SNPs for the ‘risk’ allele, the allele that increased the
probability of being a case. Accordingly, ‘0’ indicated the subject
was homozygous for the non-risk allele; the heterozygote was
coded ‘1’, and those who were homozygous for the risk allele were
coded ‘2’. Interaction effects between SNPs were modeled using
four mutually exclusive levels: (1) subjects without either risk allele,
(2) subjects with one risk allele in the first SNP but without the risk
allele in the second SNP, (3) subjects without the risk allele in the
first SNP but with the risk allele in the second SNP, and (4)
subjects with both risk alleles. Level (1), was considered the
reference group [34,35].
Multifactor dimensionality reduction (MDR, V2.0 Beta 2) was
used to verify our interaction results. MDR was initially
introduced by Ritchie et al., 2001, [36] as a genetically model-
free and non-parametric alternative to logistic regression [27,37].
A benefit of these non-parametric models is minimizing statistical
issues that frequently arise when using traditional parametric
models such as logistic regression. In particular, the possibility
often exists that few or no observations will be assigned to
contingency table cells when testing for interactions, thereby
invalidating the resulting parameter estimates. Briefly, MDR acts
by reducing a set of multilocus genotypes to one dimension with
two groups: a high-risk and a low-risk set of genotypes. A
particular multilocus genotype can be declared to be high-risk if
the ratio of number of cases to controls exceeds the proportion of
cases in the total sample. By grouping the high-risk multilocus
genotypes together and the low-risk genotypes together, the model
SNP Epistasis & Ashkenazim T2D
PLoS ONE | www.plosone.org 2 March 2010 | Volume 5 | Issue 3 | e9903is reduced to one dimension, that is, essentially 1 variable with 2
possible values: high or low risk 2-locus genotypes. Models are
evaluated on the testing balanced accuracy statistic (TBA) [38], the
cross-validation consistency (CVC) [39], and the statistical signif-
icance of the model. The TBA measures how often individuals are
correctly classified with respect to their case/control status, and the
cross-validation consistency (CVC) evaluates the consistency with
which individuals are classified. Heuristically, a satisfactory TBA
score is above 0.55 (http://compgen.blogspot.com/2006/12/mdr-
101-part-4-results.html). We used 10,000 permutations to deter-
mine the statistical significance of the best models. These data were
also analyzed using an extension of the MDR algorithm that
includes adjustment for covariates, the Generalized Multifactor
Dimensionality Reduction (GMDR, V0.7) software package [40].
Results
All SNPs were in Hardy-Weinberg equilibrium [P.0.23].
Characteristics of the cases and controls are displayed in Table 1.
As expected, BMI was significantly greater among cases than
controls [29.5 vs. 25.9, P#0.0001]. Although there were
significantly more males among cases than controls [49% vs.
42%, P=0.002], the proportion among the controls recruited in
Israel versus the U.S. did not differ [P=0.82]. The age variable
was highly correlated with the diagnosis of T2D; the mean age of
examination for controls was 72 (69.3) years versus 47 (67.8)
years for diagnosis of cases (p,0.0001). Accordingly, this variable
was not included in the statistical analyses. The average age of
cases when ascertained for this study was 64 years. Means and
standard deviations for cases’ HbA1c measurements and fasting
glucose for controls are displayed in Table 1. HbA1c measures on
controls were not recorded since at the time of ascertainment it
was not an accepted diagnostic tool. Since glucose is totally
controlled by treatment and can vary considerably from day to
day, fasting glucose was not measured in the cases.
As seen in Table 2, the genotype frequencies between cases
and controls were significantly different for the HNF4A and
WFS1 genotypes [P,0.0001, ,0.0008, respectively]. We note that
Ashkenazi cases had a greater excess of heterozygous and homo-
zygous HNF4A genotypes with the risk allele than expected by
chance, indicating a dominant mode of inheritance. Conversely,
WFS1 case/control genotypes indicate a recessive mode of inheri-
tance. Diverging from the results of multiple recent studies in non-
Ashkenazi populations [41], the TCF7L2 genotype frequencies
between cases and controls only minimally differed (P=0.055), and
the KCNJ11 genotypes showed no difference with the diagnostic
status of the Ashkenazi subjects [P,0.55]. The OR and P-values of
the logistic regression analyses on the additive genetic models for
eachSNP, with and without covariates, are displayed in Table 3. Of
the four SNPs genotyped, only the HNF4A and WFS1 SNPs were
significant with or without covariates after a Bonferroni correction
for multiple tests; the P-value for rs12255372 in TCF7L2 was 0.02.
Table 4 presents the results of models for the interaction effects of
the genotypes. The risk of a diagnosis for T2D is greatest in subjects
with the HNF4A and WFS1 SNP risk alleles versus those with
neither risk allele [OR=3.0, 95% CI=1.7–5.3]. There is no or
Table 1. Ashkenazi Sample Characteristics.
Cases
N=974
Controls
N=896
Cases vs.
Controls
Category Mean 6 STD Mean 6 STD P-value
Age
(1) 47.167.8 72.369.3 ,0.0001
BMI 29.465.0 25.86 4.2 ,0.0001
Sex (% male) 49.5 42.2 0.0018
Smoking (% Current) 11.6 10.4 0.61
Fasting Glucose (mmol/L)
(2) NA 92.5637.3
HbA1c
(2) 7.961.5 NA
Site (% Israeli) 100.0 69.9 ,0.0001
(1)Age at diagnosis for cases; age at examination for controls.
(2)Fasting Glucose was measured only in controls; HbA1c was measured only in
cases.
doi:10.1371/journal.pone.0009903.t001
Table 2. Case and Control Genotype Frequencies.
Gene (rs number) Genotype Cases (%) Controls (%)
HNF4A (20q12-q13.1) CC 276(52.5) 473(66.1)
(rs1884613) CG 200(38.0) 215(30.1)
GG 50(9.5) 27(3.8)
Total 526(42.4) 715(57.6)
X
2 2df (P value) 31.2 (,0.0001)
MAF 0.23
KCNJ11 (11p15.1) AA 79(13.8) 100(11.7)
(rs 5219) AG 266(46.4) 404(47.9)
GG 228(39.8) 339(40.2)
Total 573(40.5) 843(59.5)
X
2 2df (P value) 1.18 (0.55)
MAF 0.36
TCF7L2 (10q25.3) GG 217(37.7) 332(44.2)
(rs12255372) GT 281(48.8) 334(44.4)
TT 78(13.5) 86(11.4)
Total 576(43.4) 752(56.6)
X
2 2df (P value) 5.82(0.055)
MAF 0.35
WFS1 (4p16,1) CC 441(52.3) 318(44.6)
(rs10010131) CT 343(40.7) 313(43.9)
TT 59(7.0) 82(11.5)
Total 843(54.2) 713(45.8)
X
2 2df (P value) 14.30 (0.0008)
MAF
(1) 0.30
(1)The ‘risk’ allele for the WFS1 SNP is the major allele, C. The risk allele for all
other SNPs is the minor allele.
doi:10.1371/journal.pone.0009903.t002
Table 3. Associations between SNPs in candidate genes and
T2D in the Ashkenazi population.
OR[95% CI]
(1) P-value OR[95% CI]
(2) P-value
HNF4A (rs1884613) 1.69[1.40–2.03] ,0.0001 1.77[1.39–2.24] ,0.0001
KCNJ11 (rs5219) 1.05[0.90–1.23] 0.52 1.02[0.83–1.26] 0.83
TCF7L2 (rs12255372) 1.21[1.03–1.42] 0.02 1.21[0.98–1.49] 0.07
WFS1 (rs10010131) 1.34[1.15–1.56] ,0.0002 1.30[1.06–1.58] 0.01
(1)Unadjusted.
(2)Adjusted by sex, BMI.
doi:10.1371/journal.pone.0009903.t003
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one risk allele is present: OR=1.8 [95% CI=1.1–3.2] for the
presence of the WFS1 risk allele but not the HNF4A risk allele, and
OR=1.8 [95% CI=0.8–4.1] for the presence of the HNF4A risk
allele but not the WFS1 risk allele. As noted in Table 3, the odds of
T2D for subjects with the TCF7L2 risk allele was 1.2 times greater
than subjects without the risk allele in the single SNP logistic
regression model. However, when coupled with either the HNF4 or
WFS1 genotype containing at least one risk allele, the unadjusted
odds of being affected increased, respectively, to 2.4 and 2.9 times
greater for subjects with the TCF7L2 risk allele than those with
neither risk allele. There was no evidence for an increased risk for
T2D due to the presence of the rs5219 [KCNJ11] risk allele
interacting with any other risk alleles, with or without covariates.
Results from the multilocus MDR and GMDR analyses are
summarized in Table 5. The CVCs indicate consistency in the cross
validation measures (10/10) across all models. Based on the testing
balanced accuracy (TBA) statistic and permutation p-values, the
mostsignificantinteractions,adjustedand unadjustedforcovariates,
were pairs containing the HNF4A SNP: HNF4A x KCNJ11
(P=0.001), HNF4A x TCF7L2 (P=0.03), and HNF4A x WFS1
(P=0.009). Adding covariates strengthened the results for HNF4A
x TCF7L2 (P,0.002) and HNF4A x WFS1 (P,0.004) interactions.
TCF7L2 x WFS1 (P=0.01) was also significant, but not with the
inclusion of covariates. Over all, the parametric and nonparametric
results were consistent for the significant interactions between
HNF4A x KCNJ11, HNF4A x TCF7L2, and HNF4A x WFS1.
Consistency between the logistic regression and MDR methods was
also observed in the KCNJ11 x TCF7L2 analyses in which neither
method indicated a significant interaction between the SNPs in
these genes. The KCNJ11 x WFS1 interaction was not significant in
the MDR analyses nor in the logistic regression if no WFS1 risk
allele was present. Higher order three way unadjusted MDR
interactions were nominally significant only if the HNF4A SNP was
one of the interacting SNPs. Among the three-way unadjusted
interactions,HNF4A xKCNJ11xTCF7L2wasthemost significant
interaction: P#0.001 (Table 5). To compare the parametric and
non-parametric methods, we analyzed the same three SNPs using
logistic regression, albeit, in contrast to an MDR or GMDR
analysis, contingency table cells that contain few or no observations
would result in unstable results, a situation that may occur when
interactions are introduced into the model [42]. A significant
association with T2D was found: OR=2.4, CI=[1.5–4.0],
P#0.0006. We also note that the MDR interaction between all
four SNPs was not significant without inclusion of sex and BMI. But
that increase was extremely modest (P=0.03).
Discussion
Ourmain finding is that genetic interactionsmodulate theriskfor
T2Dinthe Ashkenazicase-controlsample.Specifically,thestrength
of the association between polymorphisms of the HNF4A and
WFS1 genes and T2D in the parametric analyses indicated a three
foldincreasedriskofT2D forindividualswhocarrytheriskallelesof
these polymorphisms compared to individuals whose genotypes
contain neither risk allele. This interaction was also echoed in the
MDR/GMDR analysis. Although the TCF7L2 SNP was not
strongly associated with T2D in this population, when TCF7L2 was
jointly analyzed with either of the HNF4A or WFS1 SNPs, more
than a two-fold increase in T2D risk was observed for subjects with
both risk alleles. This was also borne out in the nonparametric
MDR/GMDR analyses. While this phenomena has been discussed
in a theoretical context [14] and has been shown to exist in animal
models [15,16], it has not commonly been seen in human studies,
particularly one with thousands of variants, such as a GWA study in
which any SNPs that are not highly significant are often not
included in follow-up interaction or non-interaction studies. In this
analysis there was no evidence that the KCNJ11 SNP, rs5219,
altered the strength of the association in the parametric analysis
when paired with any other candidate SNP. The apparent
importance of rs5219 in the nonparametric interaction analysis
may have been the result of the presence of rs1884613 [HNF4A] in
the interaction models. However, it is difficult to understand the
disparity in the significance between the nonparametric HNF4A x
KCNJ11 x TCF7L2 interaction (P#0.001), and the HNF4A x
TCF7L2 x WFS1 interaction (P#0.01) given the significance of the
WFS1 versus the KCNJ11 SNPs in the logistic regression analyses.
To the best of our knowledge, this is the first time a significant
genetic interaction effect associated with T2D was reported in a
sample of Ashkenazi Jewish descent.
Among those who have reported on studies involving variants in
genes of interest in the current study is Weeden et al., 2006 [13]
who examined the relationship among rs5219 in the KCNJ11
gene, rs7903146 in TCF7L2, a SNP in high LD with rs12255372
(r
2=0.75), and Pro12 in the PPARG gene in a sample of over
Table 4. Odds ratios and 95% Confidence Intervals (CIs) for
the Joint Effects of Candidate SNP Genotypes on Type 2
Diabetes.
Risk Risk Ashkenazi Sample
Gene Pair Allele 1
(1) Allele 2
(1) OR(95% CI)
(2) OR(95% CI)
(3)
HNF4A, KCNJ11 221.00 1.00
(rs1884613, 2 + 1.21(0.88–1.66) 1.06(0.73–1.55)
rs 5219) + 2 1.95(1.34–2.83) 2.25(1.40–3.62)
++1.96(1.39–2.77) 1.82(1.19–2.76)
HNF4A, TCF7L2 221.00 1.00
(rs1884613, 2 + 1.43(1.05–1.96) 1.33(0.91–1.94)
rs12255372) + 2 1.88(1.29–2.74) 1.89(1.19–3.01)
++2.43(1.72–3.42) 2.47(1.61–3.78)
HNF4A, WFS1 221.00 1.00
(rs1884613, 2 + 1.82(1.05–3.17) 1.86(0.99–3.49)
rs10010131) + 2 1.80(0.78–4.11) 2.46(0.91–6.63)
++2.99(1.70–5.27) 3.27(1.71–6.26)
KCNJ11,TCF7L2 221.00 1.00
(rs 5219, 2 + 1.24(0.87–1.76) 1.16(0.73–1.82)
rs12255372) + 2 1.03(0.72–1.46) 0.89(0.57–1.39)
++1.34(0.97–1.85) 1.17(0.77–1.78)
KCNJ11,WFS1 221.00 1.00
(rs 5219, 2 + 2.32(1.21–4.46) 2.70(1.30–5.60)
rs10010131) + 2 1.71(0.74–3.98) 2.04(0.78–5.31)
++2.32(1.22–4.41) 2.17(1.07–4.44)
TCF7L2,WFS1 221.00 1.00
(rs12255372, 2 + 2.18(0.97–4.90) 2.18(0.87–5.45)
rs10010131) + 2 1.60(0.62–4.09) 1.68(0.58–4.85)
++2.87(1.28–6.40) 2.69(1.09–6.66)
(1)Risk alleles 1 and 2 refer to the leftmost and rightmost genes in the ‘Gene
Pair’column. ‘2’ indicates absence of the risk allele; ‘+’ indicates presence of
the risk allele; allele1 and allele2=‘2’ is the reference group.
(2)Unadjusted.
(3)Adjusted for Sex, BMI.
doi:10.1371/journal.pone.0009903.t004
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were found, a strong positive relationship between the numbers of
risk alleles within a subject and risk of T2D was reported: subjects
with all six risk alleles had an OR of 5.7 [95% CI=1.2–28.3] for
T2D compared to subjects with no risk alleles. Cauchi et al., 2008
[6] chose 22 SNPs in 14 loci from a previous GWA study to
replicate in four independent European samples, including an
Israeli Ashkenazi and Moroccan sample. However, they only
analyzed interaction effects in the French subset of their sample,
and none of their loci overlapped with any of those analyze in the
current study. Using MDR, Qi et al. [9] reported an interaction
between rs5219 in KCNJ11 and rs2144908 in HNF4A in a case-
control study of T2D in a sample of female subjects from the
Nurses’ Health Study. We note that rs2144908 is in complete LD
with rs1884613, r
2=1. Therefore, our MDR finding of an
interaction between rs5219 and rs1884613 in the Ashkenazi
sample is a replication of the Qi et al. study. To the best of our
knowledge, Qui et al. was the first to report an interaction between
SNPs in the HNF4A and KCNJ11 genes.
A strength of the current study is that all subjects with T2D
were Ashkenazi Jews living in Israel. Almost 70% of the controls
were also ascertained in Israel, with the remainder Ashkenazi Jews
from the U.S. No differences were detected between the two
groups of controls regarding smoking status, BMI, or gender. By
choosing Ashkenazi Jews for both cases and controls, we have
minimized the potential of genetic heterogeneity. An additional
strength of this study is that the mean age at ascertainment of non-
T2D status in the control population was 76 years, whereas the
mean age of T2D diagnosis in the cases was 25 years less, adding
to the confidence that this control group is not at high risk for a
future diagnosis. Furthermore, the average age at diagnosis of the
cases was 47 years, relatively young, and therefore more likely to
be genetically predisposed to T2D [43].
A major challenge for studies such as ours and those that
investigate the interaction betw e e nt h o u s a n d so fv a r i a n t si st o
decipher the complexity of the genetic networks between the loci that
appear to have a statistical relationship [44]. In this study, we know
that WFS1 appears to be part of the mechanisms related to beta-cell
survival [45], and HNF4a may have proliferative and/or functional
effects. The functional effects may interact with survival–increased
function resulting in increased endoplasmic reticulum (ER) and/or
oxidative stress resulting in increased apoptosis. Inactivating
mutations in HNF4a have been shown to cause hyperinsulinemic
hypoglycemia during the fetal and newborn period, as well as
MODY diabetes in adolescence [46]. We still know very little about
whether T2D associated variants effects increased or decreased
expression of HNF4A. The mechanism for such effect is still not well
understood. Therefore it would be pure speculation to try to explain
the interactions found in this study on the basis of known function.
In conclusion, all four chromosomal regions investigated in this
study harbor T2D genetic variants that have been replicated in
published studies, but very few studies have considered their
interactions. Nevertheless, we fully expect that additional variants,
some rare, will be added to the growing list of polymorphisms that
influence T2D, and that the analyses of interacting variants will lead
to a better understanding of the biological pathways underlying
T2D. This knowledge will bring us closer to the development of
effective prevention and treatment strategies.
Table 5. Gene x Gene Interaction Models: MDR (without covariates) and GMDR (with covariates).
Interacting SNPs Covariates Number of Subjects CVC
(1) TBA
(2) 10,000 Permutations P-value
HNF4A x KCNJ11 none 1162 10/10 0.560 0.001
Sex,BMI 853 10/10 0.564 0.002
HNF4A x TCF7L2 none 1153 10/10 0.540 0.028
Sex,BMI 848 10/10 0.565 0.002
HNF4A x WFS1 none 1176 10/10 0.546 0.009
Sex,BMI 829 10/10 0.559 0.004
KCNJ11 x TCF7L2 none 1288 10/10 0.504 0.437
Sex,BMI 918 10/10 0.495 0.595
KCNJ11 x WFS1 none 1117 10/10 0.516 0.252
Sex,BMI 813 10/10 0.528 0.146
TCF7L2 x WFS1 none 1111 10/10 0.546 0.010
Sex,BMI 812 10/10 0.535 0.090
HNF4A x KCNJ11 x TCF7L2 none 1122 10/10 0.565 0.001
Sex,BMI 836 10/10 0.546 0.040
HNF4A x KCNJ11 x WFS1 none 1105 10/10 0.541 0.031
Sex,B MI 802 10/10 0.549 0.034
HNF4A x TCF7L2 x WFS1 none 1096 10/10 0.551 0.011
Sex,BMI 798 10/10 0.540 0.072
KCNJ11 xTCF7L2 x WFS1 none 1080 10/10 0.528 0.122
Sex,BMI 799 10/10 0.497 0.549
HNF4A x KCNJ11 x TCF7L2 x WFS1 none 1068 10/10 0.512 0.313
Sex,BMI 788 10/10 0.552 0.029
(1)Cross Validation Consistency.
(2)Testing Balanced Accuracy.
doi:10.1371/journal.pone.0009903.t005
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